SCHEMBL2411348

SCHEMBL2411348

COc1ccc(/C=C/c2nc(CC3CCN(C(C)C)CC3)no2)cc1OC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 2/20 0.42
MAPT P10636 7/20 0.42
SMN1; SMN2 Q16637 2/20 0.40
GAA P10253 1/20 0.38
TLR9 Q9NR96 1/20 0.38
TLR8 Q9NR97 1/20 0.38
TLR7 Q9NYK1 1/20 0.38
ALDH1A1 P00352 1/20 0.37
HPGD P15428 1/20 0.37
SLC5A7 Q9GZV3 2/20 0.36
NQO2 P16083 1/20 0.36
BCHE P06276 1/20 0.36
MAOA P21397 1/20 0.36
ACHE P22303 1/20 0.36
MAOB P27338 1/20 0.36
TUBB4A P04350 1/20 0.36
TUBB P07437 1/20 0.36
TUBA3C P0DPH7 1/20 0.36
TUBA1B P68363 1/20 0.36
TUBA4A P68366 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2407227 0.86 MAPT (0.48) ALOX5MAPTSMN1; SMN2GAAALDH1A1
SCHEMBL2407229 0.86 MAPT (0.48) ALOX5MAPTSMN1; SMN2GAAALDH1A1
SCHEMBL2468734 0.84 ALOX5 (0.35) ALOX5MAPTSMN1; SMN2GAAALDH1A1
SCHEMBL2468731 0.84 ALOX5 (0.35) ALOX5MAPTSMN1; SMN2GAAALDH1A1
SCHEMBL2409068 0.84 ALOX5 (0.45) ALOX5MAPTSMN1; SMN2GAAALDH1A1
SCHEMBL2409066 0.84 ALOX5 (0.45) ALOX5MAPTSMN1; SMN2GAAALDH1A1
SCHEMBL2408654 0.83 ACHE (0.54) ALOX5MAPTBCHEACHE
SCHEMBL2407869 0.83 KDM4E (0.41) ALOX5MAPTSMN1; SMN2ALDH1A1BCHE
SCHEMBL2407867 0.83 KDM4E (0.41) ALOX5MAPTSMN1; SMN2ALDH1A1BCHE
SCHEMBL2408651 0.83 ACHE (0.54) ALOX5MAPTBCHEACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8629277-B2 Styrenyl 1,2,4-oxadiazole compounds Piramal Enterprises Limited (IN) 2014-01-14 US claimed
US-20130005771-A1 OXADIAZOLE COMPOUNDS, THEIR PREPARATION AND USE Piramal Enterprises Limited (IN) 2013-01-03 US claimed
EP-2539327-A1 OXADIAZOLE COMPOUNDS, THEIR PREPARATION AND USE Piramal Enterprises Limited (IN) 2013-01-02 EP claimed
WO-2011104680-A1 OXADIAZOLE COMPOUNDS, THEIR PREPARATION AND USE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-09-01 WO claimed
US-8629277-B2 Styrenyl 1,2,4-oxadiazole compounds Piramal Enterprises Limited (IN) 2014-01-14 US disclosed
US-20130005771-A1 OXADIAZOLE COMPOUNDS, THEIR PREPARATION AND USE Piramal Enterprises Limited (IN) 2013-01-03 US disclosed
EP-2539327-A1 OXADIAZOLE COMPOUNDS, THEIR PREPARATION AND USE Piramal Enterprises Limited (IN) 2013-01-02 EP disclosed
WO-2011104680-A1 OXADIAZOLE COMPOUNDS, THEIR PREPARATION AND USE PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130005771-A1 OXADIAZOLE COMPOUNDS, THEIR PREPARATION AND USE MCL1, OXA1L, ABL1 ALOX5 918/4885MAPT 365/4885SMN1; SMN2 274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.